Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR Colon Cancer (adults & peds ≥2 yrs).
Take-home: Subcutaneous Tecentriq Hybreza also approved (≥12 yrs, ≥40 kg). Approval based on ATOMIC (NCT02912559): DFS HR 0.50 (95% CI 0.35–0.73; p=0.0001). 3-yr DFS ~86.3% vs 76.2%. Median DFS NR either arm.
About this highlight
- Type
- Regulatory news
- Topic
- Gastrointestinal
